BOLT BIOTHERAPEUTICS INC (BOLT) Stock Price, Quote, News and Overview
NASDAQ:BOLT - Nasdaq - US0977021049 - Common Stock - Currency: USD
BOLT Quote, Performance and Key Statistics
NASDAQ:BOLT (2/21/2025, 9:47:03 AM)
0.5019
-0.01 (-1.57%)
The current stock price of BOLT is 0.5019 USD. In the past month the price decreased by -3.79%. In the past year, price decreased by -58.2%.
BOLT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.92 | 356.17B | ||
| AMGN | AMGEN INC | 15.04 | 160.11B | ||
| GILD | GILEAD SCIENCES INC | 23.97 | 137.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1674.59 | 124.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.29 | 76.27B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.60B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.32B | ||
| NTRA | NATERA INC | N/A | 22.03B | ||
| BIIB | BIOGEN INC | 8.47 | 20.33B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.09B |
Related stock screener links
About BOLT
Company Profile
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 100 full-time employees. The company went IPO on 2021-02-05. The firm's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. The company developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. The company is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Company Info
BOLT BIOTHERAPEUTICS INC
900 Chesapeake Drive
Redwood City CALIFORNIA 94063 US
CEO: Randall C. Schatzman
Employees: 100
Company Website: https://boltbio.com/
Investor Relations: https://investors.boltbio.com/
Phone: 16506659295
BOLT BIOTHERAPEUTICS INC / BOLT FAQ
What is the stock price of BOLT BIOTHERAPEUTICS INC today?
The current stock price of BOLT is 0.5019 USD. The price decreased by -1.57% in the last trading session.
What is the ticker symbol for BOLT BIOTHERAPEUTICS INC stock?
The exchange symbol of BOLT BIOTHERAPEUTICS INC is BOLT and it is listed on the Nasdaq exchange.
On which exchange is BOLT stock listed?
BOLT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BOLT BIOTHERAPEUTICS INC stock?
9 analysts have analysed BOLT and the average price target is 1.79 USD. This implies a price increase of 255.65% is expected in the next year compared to the current price of 0.5019. Check the BOLT BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BOLT BIOTHERAPEUTICS INC worth?
BOLT BIOTHERAPEUTICS INC (BOLT) has a market capitalization of 19.21M USD. This makes BOLT a Nano Cap stock.
How many employees does BOLT BIOTHERAPEUTICS INC have?
BOLT BIOTHERAPEUTICS INC (BOLT) currently has 100 employees.
What are the support and resistance levels for BOLT BIOTHERAPEUTICS INC (BOLT) stock?
BOLT BIOTHERAPEUTICS INC (BOLT) has a support level at 0.46 and a resistance level at 0.52. Check the full technical report for a detailed analysis of BOLT support and resistance levels.
Is BOLT BIOTHERAPEUTICS INC (BOLT) expected to grow?
The Revenue of BOLT BIOTHERAPEUTICS INC (BOLT) is expected to grow by 11.78% in the next year. Check the estimates tab for more information on the BOLT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BOLT BIOTHERAPEUTICS INC (BOLT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BOLT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BOLT, evaluating the profitability, health, valuation and growth aspects
- BOLT BIOTHERAPEUTICS INC (BOLT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BOLT BIOTHERAPEUTICS INC (BOLT) Sales and EPS estimates to see what analysts future expectations are.
- BOLT BIOTHERAPEUTICS INC (BOLT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BOLT BIOTHERAPEUTICS INC (BOLT) Insider and Institutional Ownership to learn about the owners and their transactions.
- BOLT BIOTHERAPEUTICS INC (BOLT) Stock Chart to make your own analysis
- BOLT BIOTHERAPEUTICS INC (BOLT) Latest news and press-releases to stay up to date.
Does BOLT BIOTHERAPEUTICS INC (BOLT) stock pay dividends?
BOLT does not pay a dividend.
When does BOLT BIOTHERAPEUTICS INC (BOLT) report earnings?
BOLT BIOTHERAPEUTICS INC (BOLT) will report earnings on 2025-03-19, after the market close.
What is the Price/Earnings (PE) ratio of BOLT BIOTHERAPEUTICS INC (BOLT)?
BOLT BIOTHERAPEUTICS INC (BOLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
What is the Short Interest ratio of BOLT BIOTHERAPEUTICS INC (BOLT) stock?
The outstanding short interest for BOLT BIOTHERAPEUTICS INC (BOLT) is 0.29% of its float. Check the ownership tab for more information on the BOLT short interest.
BOLT Technical Analysis
BOLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BOLT. While BOLT seems to be doing ok healthwise, there are quite some concerns on its profitability.
BOLT Financial Highlights
Over the last trailing twelve months BOLT reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS increased by 14.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.53% | ||
| ROE | -90.36% | ||
| Debt/Equity | 0 |
BOLT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to BOLT. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 10.08% and a revenue growth 11.78% for BOLT